Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor

被引:97
作者
Yoshikawa, S. [1 ]
Kukimoto-Niino, M. [1 ]
Parker, L. [1 ]
Handa, N. [1 ]
Terada, T. [1 ]
Fujimoto, T. [1 ]
Terazawa, Y. [1 ]
Wakiyama, M. [1 ]
Sato, M. [3 ]
Sano, S. [3 ]
Kobayashi, T. [3 ]
Tanaka, T. [3 ]
Chen, L. [4 ]
Liu, Z-J [4 ]
Wang, B-C [4 ]
Shirouzu, M. [1 ]
Kawa, S.
Semba, K. [5 ]
Yamamoto, T. [2 ,6 ]
Yokoyama, S. [1 ,7 ]
机构
[1] Yokohama Inst, RIKEN Syst & Struct Biol Ctr, Yokohama, Kanagawa 2300045, Japan
[2] Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan
[3] Japan Aerosp Explorat Agcy, Ibaraki, Japan
[4] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA
[5] Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Tokyo, Japan
[6] Okinawa Inst Sci & Technol, Cell Signal Unit, Okinawa, Japan
[7] Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan
关键词
EGFR; T790M; gefitinib; tyrosine kinase inhibitor; NSCLC; drug resistance; EGFR KINASE INHIBITORS; DIFFRACTION DATA; MUTATIONS; GEFITINIB; ACTIVATION; RESISTANT; TRANSFORMATION; REFINEMENT; MECHANISM; SOFTWARE;
D O I
10.1038/onc.2012.21
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain. The non-small cell lung cancer (NSCLC)-associated EGFR mutants, L858R and G719S, are constitutively active and oncogenic. They display sensitivity to TK inhibitors, including gefitinib and erlotinib. In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants. In this study, our biochemical analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant. The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity. The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant. Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation. The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands. In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop. Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity. Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-associated EGFR mutations. Oncogene (2013) 32, 27-38; doi:10.1038/onc.2012.21; published online 20 February 2012
引用
收藏
页码:27 / 38
页数:12
相关论文
共 48 条
[41]   A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells [J].
Wood, ER ;
Truesdale, AT ;
McDonald, OB ;
Yuan, D ;
Hassell, A ;
Dickerson, SH ;
Ellis, B ;
Pennisi, C ;
Horne, E ;
Lackey, K ;
Alligood, KJ ;
Rusnak, DW ;
Gilmer, TM ;
Shewchuk, L .
CANCER RESEARCH, 2004, 64 (18) :6652-6659
[42]   Design and Synthesis of Tetrahydropyridothieno[2,3-d]pyrimidine Scaffold Based Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors: The Role of Side Chain Chirality and Michael Acceptor Group for Maximal Potency [J].
Wu, Chia-Hsien ;
Coumar, Mohane Selvaraj ;
Chu, Chang-Ying ;
Lin, Wen-Hsing ;
Chen, Yi-Rong ;
Chen, Chiung-Tong ;
Shiao, Hui-Yi ;
Rafi, Shaik ;
Wang, Sing-Yi ;
Hsu, Hui ;
Chen, Chun-Hwa ;
Chang, Chun-Yu ;
Chang, Teng-Yuan ;
Lien, Tzu-Wen ;
Fang, Ming-Yu ;
Yeh, Kai-Chia ;
Chen, Ching-Ping ;
Yeh, Teng-Kuang ;
Hsieh, Su-Huei ;
Hsu, John T. -A. ;
Liao, Chun-Chen ;
Chao, Yu-Sheng ;
Hsieh, Hsing-Pang .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (20) :7316-7326
[43]   LAFIRE:: software for automating the refinement process of protein-structure analysis [J].
Yao, M ;
Zhou, Y ;
Tanaka, I .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2006, 62 :189-196
[44]   The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP [J].
Yun, Cai-Hong ;
Mengwasser, Kristen E. ;
Toms, Angela V. ;
Woo, Michele S. ;
Greulich, Heidi ;
Wong, Kwok-Kin ;
Meyerson, Matthew ;
Eck, Michael J. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (06) :2070-2075
[45]   Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity [J].
Yun, Cai-Hong ;
Boggon, Titus J. ;
Li, Yiqun ;
Woo, Michele S. ;
Greulich, Heidi ;
Meyerson, Matthew ;
Eck, Michael J. .
CANCER CELL, 2007, 11 (03) :217-227
[46]   An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor [J].
Zhang, Xuewu ;
Gureasko, Jodi ;
Shen, Kui ;
Cole, Philip A. ;
Kuriyan, John .
CELL, 2006, 125 (06) :1137-1149
[47]   Discovery of selective irreversible inhibitors for EGFR-T790M [J].
Zhou, Wenjun ;
Ercan, Dalia ;
Jaenne, Pasi A. ;
Gray, Nathanael S. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (02) :638-643
[48]   Novel mutant-selective EGFR kinase inhibitors against EGFR T790M [J].
Zhou, Wenjun ;
Ercan, Dalia ;
Chen, Liang ;
Yun, Cai-Hong ;
Li, Danan ;
Capelletti, Marzia ;
Cortot, Alexis B. ;
Chirieac, Lucian ;
Iacob, Roxana E. ;
Padera, Robert ;
Engen, John R. ;
Wong, Kwok-Kin ;
Eck, Michael J. ;
Gray, Nathanael S. ;
Jaenne, Pasi A. .
NATURE, 2009, 462 (7276) :1070-1074